Lv5
1210 积分 2021-06-22 加入
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
1天前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
23天前
已完结
Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression
24天前
已完结
Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer
24天前
已完结
Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial
24天前
已完结
Outcomes of leptomeningeal disease after only vertebral osseous metastases: a real-world analysis using the TriNetX database
24天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
3个月前
已完结
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/ AKT1/ PTEN Alterations
3个月前
已关闭
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
3个月前
已完结
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
3个月前
已完结
皖公网安备34019202002308
